Benefits of Satoris Approach in Alzheimer's Diagnosis

Differences that matter for Researchers and Drug Developers

Satoris biomarker tests provide the pharmaceutical community with protein panels of biomarkers, representing multiple disease processes and pathways that are especially useful in heterogeneous and dynamic diseases.  In addition to potential future applications in disease diagnosis, these panels can also provide insight into potential targets for future therapies.

• Minimally invasive sample collection - Utilizes blood samples, routinely collected in research and clinical trial protocols
• Antibody-based analysis - Enables the identification and quantification of individual proteins associated with a particular disease state
• Multivariate analysis - As opposed to tests based on only one or two biomarkers, offers greater potential significance and accuracy in assessing this complex disease process in a heterogeneous population

Differences that will matter for patients and physicians

Satoris expects to develop, validate, and gain regulatory approval for diagnostic tests that will offer significant benefits:

• Simplicity. The Satoris tests are based on blood rather than cerebro-spinal fluid, for minimally invasive sample collection. The tests will require minimal sample preparation and fewer processing steps than nucleic acid or mass spec procedures, enabling same-day turnaround of results.
• Accuracy. Studies to date, based on over 3000 samples, from more than 15 leading Alzheimer’s centers, have demonstrated that >80% accuracy may be achievable, meeting or exceeding the threshold for utility recommended by the NIA Biomarkers Working Group.
• Multivariate analysis. As opposed to tests based on only one or two biomarkers, Satoris protein biomarker panels are believed to offer greater sensitivity and specificity in diagnosing complex diseases such as Alzheimer’s disease.

The Utility of a Simple Blood Test for Alzheimer’s Diagnosis and Patient Management

Early diagnosis can enable early treatment, which means:

• Earlier stabilization or slowed progression of Alzheimer’s disease symptoms
• Improved quality of life and reduced burden to caregivers
• Delayed entrance into an institutionalized care setting
• Reduced costs of caring for individual patients and collectively, potential savings of billions of dollars to the healthcare system